Market Overview:
The global monoclonal antibodies market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for monoclonal antibody drugs, and technological advancements in the field of monoclonal antibody drug development. The global monoclonal antibodies market is segmented by type, application, and region. By type, the market is divided into erythropoietin (EPO), human growth hormone (HGH), granulocyte- colony stimulating factor (G-CSF), monoclonal antibody (mAb), insulin, interferon (IFN), and others. The mAb segment is expected to grow at the highest CAGR during the forecast period owing to its high efficacy and growing demand for targeted therapies against cancer and other chronic diseases. By application, the market is classified into anti-cancer, anti-inflammatory/autoimmune diseases such as rheumatoid arthritis or Crohn’s disease], diabetes mellitus], central nervous system disorders such as multiple sclerosis], ophthalmic disorders such as age related macular degeneration]], hematological disorders such as leukemia]].
Product Definition:
A monoclonal antibody is created by fusing a single myeloma cell with an immortalized B lymphocyte. The myeloma cells produce large numbers of identical antibodies, whereas the B lymphocytes provide the T-cell help necessary for full maturation of the antibodies.
Erythropoietin (EPO):
Erythropoietin (EPO) is a glycoprotein hormone, which controls the rate of red blood cell production. It is produced in the kidney, liver and kidney in response to hypoxia or low oxygen levels that occur when an individual is unable to breathe. An increase in erythropoietin level causes an increase in the number of red cells and thus improves oxygen delivery to tissues during times of stress or injury.
Human Growth Hormone (HGH):
Human growth hormone (HGH) is a peptide hormone that regulates the growth and development of the human body. It plays an important role in cell reproduction, tissue regeneration, and energy generation.
Application Insights:
The application segment is segregated into anti-cancer, inflammatory/ autoimmune and others. In 2017, the anti-cancer segment dominated the market with a share of over 60.0%. The growth in this segment can be attributed to increasing cancer prevalence which drives demand for monoclonal antibodies to treat cancer. According to WHO, it has been estimated that 1 in 6 women and 1 in 5 men are expected to develop cancer during their life span. This leads to huge potential demand for treatment options such as chemotherapy and radiation therapy which stimulates product innovation and development by various companies operating in the global market arena.
Monoclonal antibodies used against HIV have changed the outlook of AIDS patients from fatalistic acceptance of death sentence due largely to lack of effective drugs or therapies available till date,to optimistic expectations about future prospects regarding cure through innovative drug development using mAbs as therapeutic tools (Antibodies For Cancer Research Foundation).
Regional Analysis:
North America dominated the global monoclonal antibodies market in 2017, with a revenue share of over 40.0%. The growth is majorly attributed to the presence of key players such as Pfizer Inc.; Johnson & Johnson Services, Inc.; and Merck & Co., Inc. These companies are continuously engaged in R&D activities for development of novel products that meet unmet medical needs coupled with strong commercial sales force and high healthcare expenditure in this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing focus on improving healthcare infrastructure coupled with rising awareness regarding advanced therapeutics among patients. Moreover, growing investment by governments for development of new drugs will drive regional market during the forecast period. In addition, increasing prevalence of chronic diseases such as cancer and autoimmune disorders will boost product demand further driving growth forwarder in Asia Pacific region).
Growth Factors:
- Increasing prevalence of cancer and other chronic diseases: The increasing prevalence of cancer and other chronic diseases is one of the major growth drivers for the monoclonal antibodies market. According to the World Health Organization, in 2012, there were 14 million new cases of cancer diagnosed worldwide, and this number is expected to increase to 21 million by 2030. This will create a large demand for monoclonal antibodies for diagnosis and treatment of various cancers.
- Growing demand from emerging markets: The growing demand from emerging markets is another major growth driver for the monoclonal antibodies market. Emerging markets such as China and India are expected to experience high growth rates in the next few years due to rising income levels, population growth, and increasing awareness about healthcare products and services. This will create a large demand for monoclonal antibodies in these regions.
- Technological advancements: Monoclonal antibody technology is rapidly evolving with new technologies being developed regularly. These advancements are helping researchers develop better diagnostic tests as well as novel therapies using monoclonal antibodies that are more effective than traditional treatments methods.. This is driving the adoption of these therapies by healthcare providers which is subsequently propellingthegrowthofthemonoclona lantibodiesmarket .
Scope Of The Report
Report Attributes
Report Details
Report Title
Monoclonal Antibodies Market Research Report
By Type
Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb), Insulin, Interferon (IFN), Others
By Application
Anti-Cancer, Anti-Inflammatory/Autoimmune
By Companies
Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, SBio, Accord Healthcare, AET Biotech, Allergan, Amega Biotech, Biocon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Monoclonal Antibodies Market Report Segments:
The global Monoclonal Antibodies market is segmented on the basis of:
Types
Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb), Insulin, Interferon (IFN), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anti-Cancer, Anti-Inflammatory/Autoimmune
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocon
- Celltrion
- Dr. Reddy's Laboratories
- Hospira
- SBio
- Accord Healthcare
- AET Biotech
- Allergan
- Amega Biotech
- Biocon
Highlights of The Monoclonal Antibodies Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Erythropoietin (EPO)
- Human Growth Hormone (HGH)
- Granulocyte- Colony Stimulating Factor (G-CSF)
- Monoclonal Antibody (mAb)
- Insulin
- Interferon (IFN)
- Others
- By Application:
- Anti-Cancer
- Anti-Inflammatory/Autoimmune
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Monoclonal Antibodies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Monoclonal antibodies are a type of antibody that is made from one type of immune cell, called a B-cell. Monoclonal antibodies are used to treat diseases and conditions such as cancer, autoimmune disorders, and infections.
Some of the key players operating in the monoclonal antibodies market are Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, SBio, Accord Healthcare, AET Biotech, Allergan, Amega Biotech, Biocon.
The monoclonal antibodies market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Monoclonal Antibodies Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Monoclonal Antibodies Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Monoclonal Antibodies Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Monoclonal Antibodies Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Monoclonal Antibodies Market Size & Forecast, 2020-2028
4.5.1 Monoclonal Antibodies Market Size and Y-o-Y Growth
4.5.2 Monoclonal Antibodies Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Erythropoietin (EPO)
5.2.2 Human Growth Hormone (HGH)
5.2.3 Granulocyte- Colony Stimulating Factor (G-CSF)
5.2.4 Monoclonal Antibody (mAb)
5.2.5 Insulin
5.2.6 Interferon (IFN)
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anti-Cancer
6.2.2 Anti-Inflammatory/Autoimmune
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Monoclonal Antibodies Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Monoclonal Antibodies Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Erythropoietin (EPO)
9.6.2 Human Growth Hormone (HGH)
9.6.3 Granulocyte- Colony Stimulating Factor (G-CSF)
9.6.4 Monoclonal Antibody (mAb)
9.6.5 Insulin
9.6.6 Interferon (IFN)
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anti-Cancer
9.10.2 Anti-Inflammatory/Autoimmune
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Erythropoietin (EPO)
10.6.2 Human Growth Hormone (HGH)
10.6.3 Granulocyte- Colony Stimulating Factor (G-CSF)
10.6.4 Monoclonal Antibody (mAb)
10.6.5 Insulin
10.6.6 Interferon (IFN)
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anti-Cancer
10.10.2 Anti-Inflammatory/Autoimmune
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Erythropoietin (EPO)
11.6.2 Human Growth Hormone (HGH)
11.6.3 Granulocyte- Colony Stimulating Factor (G-CSF)
11.6.4 Monoclonal Antibody (mAb)
11.6.5 Insulin
11.6.6 Interferon (IFN)
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anti-Cancer
11.10.2 Anti-Inflammatory/Autoimmune
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Erythropoietin (EPO)
12.6.2 Human Growth Hormone (HGH)
12.6.3 Granulocyte- Colony Stimulating Factor (G-CSF)
12.6.4 Monoclonal Antibody (mAb)
12.6.5 Insulin
12.6.6 Interferon (IFN)
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anti-Cancer
12.10.2 Anti-Inflammatory/Autoimmune
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Erythropoietin (EPO)
13.6.2 Human Growth Hormone (HGH)
13.6.3 Granulocyte- Colony Stimulating Factor (G-CSF)
13.6.4 Monoclonal Antibody (mAb)
13.6.5 Insulin
13.6.6 Interferon (IFN)
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anti-Cancer
13.10.2 Anti-Inflammatory/Autoimmune
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Monoclonal Antibodies Market: Competitive Dashboard
14.2 Global Monoclonal Antibodies Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biocon
14.3.2 Celltrion
14.3.3 Dr. Reddy's Laboratories
14.3.4 Hospira
14.3.5 SBio
14.3.6 Accord Healthcare
14.3.7 AET Biotech
14.3.8 Allergan
14.3.9 Amega Biotech
14.3.10 Biocon
